Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + anlotinib + platinum doublet perioperative therapy in resectable stage II–IIIB driver-negative NSCLC
ChiCTR2600129986Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, anlotinib, cisplatin, carboplatin, pemetrexed and 1 more in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tislelizumabanlotinibcisplatincarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129986.